Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 4/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.34 |
| ▸ | CCR6 | P51684 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | CCNK | O75909 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 3/20 | 0.32 |
| ▸ | USP14 | P54578 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27251709 | 1.00 | ADORA2A (0.41) | ADORA2APCSK9PDE4BPDE4DADORA1 | |
| SCHEMBL29315308 | 0.90 | ADORA2A (0.36) | ADORA2APCSK9PDE4BPDE4DADORA1 | |
| SCHEMBL27251741 | 0.85 | ADORA2A (0.39) | ADORA2APCSK9ADORA1CCR6CCNK | |
| SCHEMBL30827696 | 0.85 | ADORA2A (0.39) | ADORA2APCSK9ADORA1CCR6CCNK | |
| SCHEMBL27251706 | 0.84 | PRKDC (0.40) | ADORA2APCSK9CCR6CCNKCCNA2 | |
| SCHEMBL27251707 | 0.84 | PRKDC (0.40) | ADORA2APCSK9ADORA1CCR6CCNK | |
| SCHEMBL31063933 | 0.84 | PRKDC (0.40) | ADORA2APCSK9ADORA1CCR6CCNK | |
| SCHEMBL31063879 | 0.84 | PRKDC (0.40) | ADORA2APCSK9CCR6CCNKCCNA2 | |
| SCHEMBL30827663 | 0.84 | ADORA2A (0.42) | ADORA2APCSK9PDE4BPDE4DADORA1 | |
| SCHEMBL27251708 | 0.84 | ADORA2A (0.42) | ADORA2APCSK9PDE4BPDE4DADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590397-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-07-30 | — | — | EP | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| WO-2024062090-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | ADORA2A 1546/4885PCSK9 1/4885PDE4B 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.